Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy.

Brain : a journal of neurology·2026
Same author

Clinical, Electrophysiological, and Neuropathological Features of Peripheral Neuropathies in People With T-Cell Lymphoproliferative Disorder.

Neurology·2026
Same author

A CSF disease-associated macrophage signature defines progressive multiple sclerosis.

Journal of neuroinflammation·2026
Same author

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments: A Multicenter Cohort Study.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

[Neurology : what's new in 2025].

Revue medicale suisse·2026

Related Experiment Video

Updated: Jun 27, 2025

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice

Published on: April 15, 2014

82.0K

[Anti-MOG associated disease].

Julien Lerusse1, Marjolaine Uginet1, Marie Théaudin2

  • 1Unité de neuro-immunologie, Service de neurologie, Département des neurosciences cliniques, Hôpitaux universitaires de Genève et Faculté de médecine, Université de Genève, 1211 Genève 14.

Revue Medicale Suisse
|April 26, 2024
PubMed
Summary
This summary is machine-generated.

Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD) is a central nervous system autoimmune disorder. This article details MOGAD

More Related Videos

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies
10:47

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies

Published on: October 27, 2016

11.0K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.6K

Related Experiment Videos

Last Updated: Jun 27, 2025

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice

Published on: April 15, 2014

82.0K
Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies
10:47

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies

Published on: October 27, 2016

11.0K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.6K

Area of Science:

  • Neuroimmunology
  • Autoimmune demyelinating diseases of the central nervous system

Context:

  • Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD) is an autoimmune disorder causing central nervous system demyelination.
  • Phenotypic overlap exists between MOGAD, multiple sclerosis (MS), and neuromyelitis optica spectrum disease (NMOSD).
  • International expert consensus established diagnostic criteria for MOGAD in 2023.

Purpose:

  • To present clinical characteristics suggestive of MOGAD.
  • To highlight the significance of antibody detection methods in MOGAD diagnosis.
  • To discuss current therapeutic management strategies for MOGAD.

Summary:

  • Presents clinical features that suggest MOGAD, an autoimmune demyelinating disease.
  • Emphasizes the role of specific antibody detection in diagnosing MOGAD.
  • Discusses treatment approaches for MOGAD, differentiating it from MS and NMOSD.

Impact:

  • Aids in improving diagnostic specificity for MOGAD.
  • Facilitates better understanding of MOGAD's clinical, biological, and imaging features.
  • Supports clinicians in managing patients with MOGAD and related disorders.